Dejan Juric
- Molecular Biology top 1%
- Oncology top 0.5%
- Pulmonary and Respiratory Medicine top 0.5%
- Cancer Research top 0.5%
- Genetics top 0.5%
- Co-authors
- Hope S. RugoIngrid A. MayerSibylle LoiblMario CamponeFabrice AndréPierfranco ContéHiroji IwataToshinari Yamashita
- Topics
- Advanced Breast Cancer Therapies (150 papers)Cancer Treatment and Pharmacology (83 papers)HER2/EGFR in Cancer Research (66 papers)
- Cited by
- OncologyCancer ResearchGenetics
- Journals
- New England Journal of MedicineProceedings of the National Academy of SciencesNature Communications
- Partner nations
- United StatesSpainFrance
In The Last Decade
Dejan Juric
243 papers receiving 7.9k citations
Hit Papers
Peers
Comparison fields: 5 of 127
- Molecular Biology 4.0k
- Oncology 3.8k
- Pulmonary and Respiratory Medicine 3.4k
- Cancer Research 2.0k
- Genetics 1.3k
Countries citing papers authored by Dejan Juric
This map shows the geographic impact of Dejan Juric's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Dejan Juric with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Dejan Juric more than expected).
Fields of papers citing papers by Dejan Juric
This network shows the impact of papers produced by Dejan Juric. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Dejan Juric. The network helps show where Dejan Juric may publish in the future.
Co-authorship network of co-authors of Dejan Juric
This figure shows the co-authorship network connecting the top 25 collaborators of Dejan Juric. A scholar is included among the top collaborators of Dejan Juric based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Dejan Juric. Dejan Juric is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 23 | |
| 2 | 2 | |
| 3 | 1 | |
| 4 | 0 | |
| 5 | 4 | |
| 6 | 12 | |
| 7 | 1 | |
| 8 | 1 | |
| 9 | 12 | |
| 10 | Clinical Acquired Resistance to KRASG12C Inhibition through a Novel KRAS Switch-II Pocket Mutation and Polyclonal Alterations Converging on RAS–MAPK Reactivationbreakdown → | 302 |
| 11 | 10 | |
| 12 | 62 | |
| 13 | Alpelisib for PIK3CA -Mutated, Hormone Receptor–Positive Advanced Breast Cancerbreakdown → | 1565 |
| 14 | 47 | |
| 15 | Phosphatidylinositol 3-Kinase α–Selective Inhibition With Alpelisib (BYL719) in PIK3CA-Altered Solid Tumors: Results From the First-in-Human Studybreakdown → | 302 |
| 16 | 120 | |
| 17 | 76 | |
| 18 | 249 | |
| 19 | 41 | |
| 20 | 126 |
About Dejan Juric
Dejan Juric is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research, having authored 252 papers that have together received 8.0k indexed citations. Recurring topics across this work include Advanced Breast Cancer Therapies (150 papers), Cancer Treatment and Pharmacology (83 papers) and HER2/EGFR in Cancer Research (66 papers). The work is most often cited by research in Oncology (3.8k citations), Cancer Research (2.0k citations) and Genetics (1.3k citations). Dejan Juric has collaborated with scholars based in United States, Spain and France. Frequent co-authors include Hope S. Rugo, Ingrid A. Mayer, Sibylle Loibl, Mario Campone, Fabrice André, Pierfranco Conté, Hiroji Iwata, Toshinari Yamashita, David Mills and Eva Ciruelos. Their work appears in journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and Nature Communications.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.